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Abstract
Glutamate is the primary excitatory amino acid neurotransmitter in the CNS. The concentration of
glutamate in the synaptic cleft is tightly controlled by interplay between glutamate release and
glutamate clearance. Abnormal glutamate release and/or dysfunction of glutamate clearance can
cause overstimulation of glutamate receptors and result in neuronal injury known as excitotoxicity.
The glial glutamate transporter EAAT2 plays a major role in glutamate clearance. Dysfunction or
reduced expression of EAAT2 has been documented in many neurodegenerative diseases. In
addition, many studies in animal models of disease indicate that increased EAAT2 expression
provides neuronal protection. Here, we summarize these studies and suggest that EAAT2 is a
potential target for the prevention of excitotoxicity. EAAT2 can be upregulated by transcriptional
or translational activation. We discuss current progress in the search for EAAT2 activators, which
is a promising direction for the treatment of neurodegenerative diseases.
Excitotoxicity: a common problem in neurodegenerative diseases
Glutamate is the main excitatory neurotransmitter in the CNS, responsible for fast excitatory
neurotransmission (Figure 1A). In nerve terminals, glutamate is stored in synaptic vesicles
from which glutamate is released in a calcium-dependent manner upon depolarization of the
nerve terminal. Glutamate release causes a significant increase of glutamate concentration
(~1000-fold) in the synaptic cleft. Released glutamate binds to ionotropic glutamate
receptors (NMDA-R and AMPA-R in Figure 1A) on postsynaptic neurons, which
stimulates an influx of Na+ and Ca2+ ions into neurons. This leads to depolarization and
generation of action potentials. Glutamate is then quickly removed from the synaptic cleft
by glutamate transporters (EAAT2 in Figure 1A) to prevent glutamate receptor
overstimulation. Glutamate taken up by perisynaptic astrocytes is then converted to
glutamine by glutamine synthetase. Following this, glutamine is transferred to neurons
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where it is converted into glutamate by glutaminase and then taken by vesicular glutamate
transporters into synaptic vesicles, where it is available for use in excitatory
neurotransmission [1].
Elevated extracellular glutamate concentrations can occur under disease conditions when the
release of glutamate from presynaptic terminals and/or glial cells is increased (Figure 1B) or
when the glutamate reuptake function is impaired (Figure 1C). Activated microglia and
reactive astrocytes release large amounts of glutamate under pathological conditions [2–3].
Excessive glutamate can cause overstimulation of glutamate receptors and lead to an
increased intracellular concentration of Na+ and Ca2+ ions. This can result in a form of
neuronal injury or death known as ‘excitotoxicity’ [4]. Excitotoxicity is thought to
contribute to a wide range of acute and chronic neurodegenerative diseases. Acute elevations
of glutamate in conditions such as stroke, neurotrauma and epilepsy cause severe neuronal
damage [5–7]. Chronic and mild elevations of glutamate underlie excitotoxicity in chronic
neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and
amyotrophic lateral sclerosis (ALS) [8–10]. Therefore, the glutamate-induced excitotoxicity
pathway has been a therapeutic strategy for neurodegenerative diseases.
N-methyl-D-aspartate (NMDA) and Ca2+-permeable α-amino-3-hydroxy-5-methyl-4
isoxazolepropionate (AMPA) receptors are considered to be mainly responsible for
excitotoxicity [4]. Blocking these receptors, especially the NMDA receptor, has been a
therapeutic strategy. However, the majority of NMDA antagonists are competitive
antagonists that cause side effects including hallucinations and schizophrenia-type
symptoms in patients [11]. The side effects likely result from the competitive antagonists
blocking physiological functions of the receptor. Memantine is a noncompetitive NMDA
receptor antagonist that can decrease pathological activation of NMDA-receptors without
affecting physiological NMDA receptor activity. This drug is available for treating the
advanced stages of AD. Memantine is a relatively safe drug with few side effects, but only
has mild clinically relevant effects on cognition, global functioning and activities of daily
living [12]. Riluzole is another marketed drug that has anti-excitotoxic properties. This drug
inhibits the release of glutamate and also blocks some of the postsynaptic effects of
glutamate by inhibition of NMDA and AMPA receptors [13]. Riluzole is the only approved
pharmacologic treatment for ALS. Riluzole is a relatively safe drug for ALS patients that
prolongs survival by approximately 2–3 months [14]. It appears that the beneficial effects of
these available anti-excitotoxic drugs are very limited. Therefore, there is a need for better
therapeutics.
EAAT2: a potential target for prevention of excitotoxicity
Another potential approach to preventing excitotoxicity is enhanced glutamate reuptake. The
concentration of glutamate in the synaptic cleft and the resultant activity of the postsynaptic
glutamate receptors are tightly regulated by the interplay between glutamate release and
glutamate clearance. Glutamate clearance is facilitated by a family of Na+- and K+-coupled
excitatory amino acid transporters (EAATs). Five mammalian EAATs have been cloned and
characterized: EAAT1 (known as GLAST in rodents) [15], EAAT2 (known as GLT-1 in
rodents) [16], EAAT3 (known as EAAC1 in rodents) [17], EAAT4 [18] and EAAT5 [19]. In
the CNS, while EAAT1 and EAAT2 are found primarily in astrocytes, EAAT3 and EAAT4
are found principally in neurons [18,20]. EAAT5 is expressed primarily in the retina [19].
However, a recent study reported that astrocytes express all EAATs, and microglia also
express all EAATs except EAAT4 [21].
The glial glutamate transporters, EAAT1 and EAAT2, are found primarily on perisynaptic
processes of astrocytes closely associated with excitatory synaptic contacts and are
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responsible for maintaining low extracellular glutamate concentrations [22]. This is
particularly the case for EAAT2, which may be responsible for up to 80–90% of all
extracellular glutamate uptake activity [23]. Mice deficient in EAAT2 develop lethal
spontaneous seizures and show increased susceptibility to acute cortical injury [24].
Dysfunction or reduced expression of EAAT2 has been documented in both chronic and
acute neurodegenerative disorders. In addition, several lines of evidence in animal models of
disease suggest that upregulation of EAAT2 is a potential therapeutic strategy for the
prevention of excitotoxicity (Figure 1D). These studies are described below.
Alzheimer’s disease
AD is a progressive neurodegenerative disease in which patients have declarative memory
impairments and progressing dementia. Early in the disease process, cortical and
hippocampal synapse density is significantly reduced. This loss of synapses strongly
correlates with memory impairments [25]. Several reports have demonstrated that glutamate
transport function is significantly reduced in AD brains. This decrease correlates with loss of
synapse and neuronal death [26–30]. Reduced glutamate transport function was found to be
associated with decreased EAAT2 protein expression in AD brains [30,31]. The mechanism
underlying the loss of EAAT2 in AD is unclear. It appears that this loss is due to
disturbances at the post-transcriptional level because EAAT2 mRNA is not decreased [30].
It has been shown that EAAT2 is oxidatively modified by the lipid peroxidation product 4-
hydroxy-2-nonenal in AD brains [32]. Oxidative damage of EAAT2 proteins could result in
their degradation and loss of function. In addition, a recent study showed that a disturbance
of cholesterol metabolism, known to occur in AD, can cause a reduction of membrane
cholesterol levels. This reduction results in dissociation of EAAT2 from lipid raft
microdomains of the plasma membrane and subsequently leads to loss of EAAT2 and
glutamate transport function [33,34].
Several studies of glutamate uptake inhibition in vivo indicate that impaired glutamate
transport function can cause neuronal death. Injection of a glutamate uptake blocker, DL-
threo-β-hydroxyaspartate, into rat striatum caused neuronal degeneration [35]. Chronic
inhibition of glutamate transport with DL-threo-β-hydroxyaspartate leads to slow neuronal
death that can be prevented by glutamate-receptor antagonists [36]. Intrahippocampal
injections of the glutamate transport inhibitor dihydokainate induce neuronal damage. This
effect can be prevented by the glutamate receptor antagonists [37].
Furthermore, our laboratory recently investigated the role of EAAT2 dysfunction in the
pathogenesis of AD in APPSw/Ind mice, a transgenic mouse of AD. Loss of EAAT2 protein
and associated functions was also found in these transgenic mice. We crossed APPSw/Ind
mice with the transgenic mice overexpressing human EAAT2 (EAAT2 transgenic mice),
which have a 1.5- to two-fold increase in EAAT2 protein levels compared with their
nontransgenic counterparts, to investigate whether supplementation of the loss of EAAT2
would have beneficial effects on disease progression. EAAT2 protein levels and the
associated glutamate-uptake functions were restored in APP/EAAT2 double transgenic
mice. Several important phenomena were observed in APP/EAAT2 mice compared with
their APP littermates. First, premature death was significantly reduced. Second, learning and
memory capacity was significantly improved. Third, several Alzheimer’s-like pathological
changes were significantly improved, including reduced amyloid plaques, increased synaptic
density and reduced glial activation [Kong Q et al., Unpublished Data]. These results
indicate that loss of EAAT2 contributes to the pathogenesis in an AD mouse model and
suggest that enhanced glutamate uptake by increasing EAAT2 expression may be a potential
therapeutic strategy for AD.
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Amyotrophic lateral sclerosis
ALS is a late-onset and fatal neurodegenerative disorder that is characterized by progressive
degeneration of motor neurons in the spinal cord, motor cortex and brainstem. This
typically results in muscle weakness, atrophy, spasticity and progressive paralysis until
death, which usually occurs within 2–5 years of symptom onset. There is currently no
effective treatment for ALS. A number of mechanisms have been implicated in the
pathogenesis of ALS, including aberrant RNA metabolism, glutamate excitotoxicity,
oxidative damage, mitochondrial dysfunction, impaired axonal transport, growth factor
deficiency and accumulation of intracellular aggregates [38]. In addition, ALS is not only a
multifactorial disease. but also a multisystemic disease that affects several cell types [39].
Approximately 60–70% of ALS patients have a 30–95% loss of the EAAT2 protein in the
motor cortex and spinal cord [40]. The loss of EAAT2 protein has also been observed in
transgenic mice or rats expressing familial ALS-linked mutant SOD1 [41–43]. Studies
indicate that the reduction in EAAT2 protein is correlated with neuronal loss. This raises an
important question as to whether loss of EAAT2 protein is a contributing factor or is simply
a consequence of motor neuron degeneration. Guo and colleagues addressed this question by
crossing transgenic mice overexpressing human mutant SOD1(G93A) with the EAAT2
transgenic mice [44]. The EAAT2/SOD1(G93A) double transgenic mice showed a
significant delay in motor function decline and motor neuron degeneration, but not in the life
span, when compared with SOD1(G93A) littermates. In addition, Rothstein and colleagues
discovered that β-lactam antibiotics were able to induce EAAT2 protein expression.
Treating SOD1(G93A) mice with ceftriaxone (Figure 2), a β-lactam antibiotic, significantly
ameliorated symptoms and prolonged survival [45]. These studies demonstrate that loss of
EAAT2 does contribute to disease progression in ALS mice and suggest that a therapeutic
approach by inducing EAAT2 protein expression may have beneficial effects to ALS
patients.
Parkinson disease
PD is a common age-related neurodegenerative disease that is caused by a progressive
degeneration of dopaminergic neurons in the pars compacta of substantia nigra (SNc).
Degeneration of SNc neurons deprives striatal neurons of their dopaminergic innervations,
which triggers complex functional modifications within the basal ganglia circuitry. This
ultimately leads to development of the motor symptoms, including bradykinesia, tremor and
rigidity [46]. Glutamate is also the predominant excitatory transmitter in the basal ganglia.
In addition to sending glutamatergic projections to the striatum, the cortex also sends
projections to the subthalamic nucleus (STN) and SNc [47]. The SNc receives further
glutamatergic innervation from the STN. The dopaminergic projections from the SNc to
various nuclei in the basal ganglia circuit perform important regulatory functions. Under
disease conditions, the reduction in the dopaminergic message to the striatum, as seen in PD,
results in an increase in firing of STN neurons. This increase functions as a compensatory
mechanism to stimulate the release of dopamine from the surviving dopaminergic neurons in
the SNc in order to maintain dopamine homeostasis [48]. However, a sustained increase in
glutamate release into already compromised dopaminergic neurons could evoke
excitotoxicity and potentiate neurodegeneration.
There is growing evidence that supports the important role of glutamatergic pathways in the
pathogenesis of PD. Evidence from mouse and primate models of PD demonstrated that
certain NMDA- and AMPA-receptor antagonists have antiparkinsonian action [49–51]. It
has been shown that mGlu2/3 receptor agonists can attenuate 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-induced dopaminergic neuron degeneration in mice [52,53]. Treatment
with mGlu5 receptor antagonists alleviated motor symptoms in parkinsonian animals [54–
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56]. Furthermore, ablation of the STN by lesion or inactivation of the STN by deep-brain
stimulation leads to a reduction in firing of the STN and blunted release of glutamate onto
the SNc. This has been shown to ameliorate the motor symptoms associated with PD and
increase survival of dopaminergic neurons in SNc [57–59]. These neuroprotections are
probably due to a reduction in glutamate excitotoxicity, as a result of the loss or reduction of
the STN input to the SNc. Therefore, antiglutamate approaches are promising.
Changes of EAAT2 expression have been reported in animal models of PD. Chung et al.
reported downregulation of EAAT2 after 6-hydroxydopamine injection into the nigrostriatal
pathway [60]. Holmer et al. reported a decrease in striatal EAAT2 immunolabeling in the
acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model [61]. However, it has not
been reported whether increased EAAT2 expression could ameliorate PD symptoms.
Epilepsy
Epilepsy is an array of diverse chronic neurological disorders characterized by seizures.
Abnormal hyper-synchronous neuronal activity in the brain causes seizures. There are two
broad categories of epilepsy syndromes: partial and generalized [62]. Partial seizures are the
most common seizure disorder in adults, often originating from lesions such as head trauma,
strokes and tumors [7]. The most prevalent of these syndromes features complex partial
seizures arising from the mesial temporal lobe, termed temporal lobe epilepsy (TLE). There
is a latent period of several years between the initial lesion and the emergence of chronic
TLE. The initial lesion causes complex molecular, biochemical and structural changes that
over time result in the development of spontaneous recurrent seizures. This process is
referred to as epileptogenesis [63]. The most common lesion in patients with TLE is
hippocampal sclerosis. There is selective loss of neurons in the dentate hilus and the
hippocampal pyramidal-cell layer; thus, patients with TLE often show impairments in
learning, memory and other cognitive functions [64].
Glutamate plays a crucial role in the initiation of seizures and their propagation. In vivo
microdialysis studies of patients with epilepsy show a significant increase in extracellular
glutamate levels, which reach neurotoxic concentrations in the hippocampus before and
during seizure onset [65,66]. It is believed that abnormal glutamate released by astrocytes
plays a causal role in the synchronous firing of large populations of neurons during seizures
[3,67–69]. In addition, glutamate transport dysfunction may contribute to high extracellular
glutamate levels in the epileptogenic hippocampus [70,71]. Brain injuries that result from
seizures occur in a dynamic process. Intense seizure activity causes excessive glutamate
release and overstimulation of glutamate receptors, which leads to massive influxes of
calcium and subsequently triggers acute neuronal cell death. Massive neuronal death
consequently causes complex modifications including synaptic plasticity, aberrant
reorganization of neuronal circuitry, alterations in interneuron number and function, and
change in dentate neurogenesis. These epileptogenic changes over time result in the
development of spontaneous recurrent seizures. Therefore, reducing glutamate-mediated
excitotoxicity may potentially prevent seizure-induced epileptogenesis. Kong et al. recently
investigated pilocarpine-induced status epilepticus in EAAT2 transgenic mice [72]. They
observed that increased EAAT2 expression can significantly prevent seizure-induced
neuronal death, epileptogenesis and subsequent recurrent seizures. This study suggests that
increased EAAT2 protein expression is a potential therapeutic approach for epilepsy.
Multiple sclerosis
Multiple sclerosis (MS) is primarily an inflammatory disease in which focal lymphocytic
infiltration results in damage of myelin sheaths around the axons of the brain and spinal
cord, leading to a broad spectrum of symptoms [73]. The early course of the disease is
Lin et al. Page 5
Future Med Chem. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
characterized by episodes of neurological dysfunction that usually recover; however, over
time the pathological changes become dominated by wide-spread microglial activation,
astrogliosis, axonal degeneration and chronic neurodegeneration. MS often progresses to
physical and cognitive disabilities.
There is growing evidence that glutamate plays a role in the pathology of MS and
experimental autoimmune encephalomyelitis (EAE), the animal model of MS. In vivo
magnetic resonance spectroscopy has shown that glutamate is elevated in MS normal-
appearing white matter and acute white matter lesions [74]. Cerebrospinal fluid glutamate
levels are significantly increased during the relapse period and correlate with disease
severity and course [75]. Oligodendrocytes and neurons are highly vulnerable to glutamate-
mediated excitotoxic damage [76]. Blockade of AMPA/kainate receptors with antagonists,
NBQX, MPQX, GYKI52466 or GYKI5377 resulted in marked reduction of neurological
deficits in the EAE model [77]. In addition, NMDA-receptor antagonists, memantine,
amantadine and MK-801 all reduce neurological deficits in the EAE model [78,79]. A study
focused on EAAT2 expression in different regions of rat brain during the course of EAE
revealed that EAAT2 protein levels in the cerebellum were significantly reduced, although
EAAT2 mRNAs were upregulated, both immediately before the acute phase and later during
the recovery phase [80]. These results suggest post-translational disturbances associated
with EAE conditions may lead to insufficient protection against glutamate excitotoxicity.
There is currently no study that reports whether increased EAAT2 expression could
ameliorate MS symptoms.
Stroke
Stroke, a leading cause of adult disability, is caused by ischemia (lack of blood flow) or a
hemorrhage (leakage of blood). The injury process begins following the interruption of
blood flow to brain tissue. If blood flow is not recovered within a short period of time, cell
death within the ischemic area will occur. Consequently, the affected area of the brain loses
function, resulting in disability or even death.
Substantial evidence indicates that glutamatemediated excitotoxicity is an important
contributor in the neuropathology of stroke. Rapidly following interruption of blood flow,
mitochondrial inhibition of ATP synthesis leads to the depletion of ATP stores in the
affected area of a stroke, which quickly leads to neuronal plasma membrane depolarization,
release of potassium into the extracellular space and entry of sodium into cells [81].
Excessive membrane depolarization and accumulation of sodium inside cells ultimately
causes glutamate release in high concentrations at the core of the infarct [82]. This causes
hyperactivation of glutamate receptors and subsequently raises intracellular calcium to high
levels, leading to excitotoxic cell death.
Glutamate release via reversal of glutamate transport plays a critical role in ischemic
pathology [83,84]. Glutamate is released from neurons rather than glia in ischemia [83],
possibly because their higher internal glutamate concentrations drive reversed uptake more
readily. Dihydrokainate (DHK), a nontransported blocker of EAAT2, has no effect on the
glutamate release in a hippocampal slice model of ischemia [83]. Therefore, increased
EAAT2 protein and function may not cause more glutamate release, but rather augment
glutamate clearance. Several studies suggest that uptake of glutamate by EAAT2 plays a
neuroprotective role after ischemia. Rao et al. reported that knockdown of EAAT2
exacerbates the transient middle cerebral artery occlusion-induced neuronal damage [85].
Weller et al. showed that overexpression of EAAT2 enhances neuroprotection following a
moderate oxygen glucose deprivation in rat hippocampal slice cultures [86]. Chu et al.
reported that ceftriaxone treatment in rats upregulated EAAT2 expression and reduced
infarct volume in the middle cerebral artery occlusion model of ischemia [87]. A recent
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study shows that focal overexpression of EAAT2 significantly reduces ischemia-induced
glutamate overflow, decreases cell death and improves behavioral recovery in a rat model of
stroke [88]. These studies suggest that EAAT2 can be a therapeutic target for stroke.
Traumatic brain injury
Traumatic brain injury (TBI) is one of the leading causes of death and disability among
children and young adults. Patients with brain injury suffer from surface contusion, focal or
diffuse intracranial hemorrhages, and diffuse axonal injuries. These primary injuries can
lead to more serious secondary events, which include alterations in cerebral blood flow and
the pressure within the skull. These secondary processes contribute substantially to the
damage from the initial injury. Glutamate excitotoxicity plays an important role in the
development of secondary injuries and contributes significantly to expansion of the total
volume of injury [5].
Following TBI, levels of extracellular glutamate increase acutely [89–91]. Glutamate may
move into the brain following disruption of the blood–brain barrier [92]. Excessive synaptic
release of glutamate occurs following the injury and leads to glutamate overflow into extra-
synaptic regions [93]. Decreased glutamate transporter activity, due either to functional
impairment or decreased EAATs protein expression can also contribute to the accumulation
of extracellular glutamate [94]. Furthermore, glutamate transporter reversal could also result
in a rise in extracellular glutamate levels. Currently, there are no reports that have
specifically investigated the role of increased EAAT2 expression in TBI animal models.
Searching for EAAT2 activators: a promising approach for the treatment of
neurodegenerative diseases
The mechanisms underlying regulation of EAAT2 expression have been extensively studied
[95–99]. Expression of EAAT2 is regulated at both the transcriptional and translational
level. Many growth factors, including EGF, TGF-α, PDGF and pituitary adenylate cyclase-
activating polypeptide, can increase EAAT2 expression through increased transcription of
the EAAT2 gene [95,96]. Expression of EAAT2 can also be regulated through increased
translation of EAAT2 transcripts [97]. Several factors including corticosterone and retinol
are able to increase translation of EAAT2 transcripts. Moreover, several disease-associated
insults affect the efficiency of EAAT2 translation, suggesting that translational
dysregulation may be involved in the loss of EAAT2 in neurodegenerative diseases.
Therefore, two approaches can be used to search for EAAT2 activators: transcriptional or
translational activation.
Searching for EAAT2 transcriptional activators
One approach to identifying small-molecule activators of EAAT2 expression would be to
utilize a reporter gene assay using the EAAT2 promoter to drive expression of a reporter,
such as luciferase. The human EAAT2 promoter has been cloned and characterized [100].
Rothstein et al. have generated primary human fetal astrocytes that stably express firefly
luciferase driven by the human EAAT2 promoter. They demonstrated that the human
EAAT2 promoter was significantly activated by ceftriaxone, amoxicillin and dibutyryl
cyclic AMP [45]. Increased expression of EAAT2 was observed 48 h after treatment. The
results of these experiments suggest that this system may be used to screen for compounds
that activate EAAT2 promoter activity. However, at this time, there is no report if this
approach successfully identifies EAAT2 transcriptional activators.
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Searching for EAAT2 translational activators
A second approach would be to screen for compounds that increase EAAT2 translation. Our
laboratories have taken this approach because of the following two reasons: loss of EAAT2
protein in patients is probably due to disturbances at the post-transcriptional level because
EAAT2 mRNA is not decreased; and, in the acute conditions such as stroke, TBI and
epilepsy, immediately upregulated EAAT2 protein and function is critical. The progress of
this drug-discovery project is briefly described below.
We developed a cell-based enzyme-linked immunosorbent assay using a primary astrocyte
line stably transfected with a vector designed to identify modulators of EAAT2 translation
[101]. This assay was optimized for high-throughput screening, and a library of
approximately 140,000 compounds was tested. In the initial screening, 293 compounds were
identified as hits (increased activation by >60%), for an initial 0.2% hit rate. After
rescreening the 293 initial hits, a total of 61 compounds were selected that showed a dose-
dependent increase of activation. Of the 61 confirmed compounds, 16 unique structural
classes were identified. The effects of these compounds on increasing EAAT2 protein level,
glutamate transport function, EAAT2 protein localization, and with no change in EAAT2
mRNA level were confirmed. These compounds provide an adequate degree of structural
diversity necessary for the foundation of a drug-discovery project.
We then analyzed the structure tractability of these compounds, and six classes were
prioritized based on structure. The compounds of these six classes were further evaluated in
mouse primary cortical neurons and astrocytes mixed cultures and then in wild-type mice by
intrathecal administration of compounds. After intensive studies with these compounds, two
lead series were selected for further investigation. Many analogs with better potency were
identified. Two analogs with higher potency (one for each lead series) were selected for in
vivo pharmacokinetics, in vivo pharmacodynamics, in vivo acute and chronic maximum
tolerated dose studies, and in vitro profiling studies. One of the lead series, a pyridazine
derivative, was further selected for SAR studies [102]. We then performed efficacy studies
in two animal models of disease including the ALS (SOD1[G93A] transgenic mouse model,
chronic excitotoxicity) and epilepsy (pilocarpine-induced limbic epilepsy model, acute
excitotoxicity) using the analog LDN-212320 (Figure 2). Our results indicate that this
compound had significant protective effects in these animal models of disease [Kong Q et
al., Unpublished Data], providing support for this approach. Further investigation into these
lead compound series is underway.
Future perspective
Glutamate-mediated excitotoxicity is involved in a wide range of acute and chronic
neurodegenerative diseases. However, there is currently no safe and effective drug for the
prevention of excitotoxicity. Glutamate-receptor antagonist treatment has not been a very
successful strategy in humans because it affects normal brain function and produces
negative side effects. There is a need for better therapeutics. Loss of EAAT2 protein and
function is commonly found in chronic neurodegenerative diseases such as ALS and AD and
may be the main cause of excitotoxicity in these diseases. Restored EAAT2 protein levels
and function may provide therapeutic benefit. In disease conditions such as epilepsy, stroke
and TBI, a dramatic increase in extracellular glutamate levels cause severe neuronal
damage. Immediate upregulation of EAAT2 protein may reduce extracellular glutamate
levels and thereby prevent damage to neurons. Therefore, increased EAAT2 expression is a
potential approach to preventing excitotoxicity in both acute and chronic neurodegenerative
diseases. EAAT2 can be upregulated by transcriptional or translational activation. β-lactam
antibiotics, such as ceftriaxone, were identified as transcriptional activators of EAAT2.
Ceftriaxone has been tested in many disease models and is capable of providing neuronal
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protection. This drug is currently in human clinical trials for ALS. It may be possible to
develop new derivatives of ceftriaxone with enhanced pharmacological and bioactivity
properties. In addition, new EAAT2 transcriptional activators may be identified in the near
future. However, the transcriptional activation approach may not work well for acute
conditions, such as those stated above, because the process from transcription to protein
production takes time. For instance, the release of glutamate occurs within minutes of
ischemic onset; therefore therapeutic drugs targeted at blocking excitotoxicity must not only
be administered rapidly, but also need to take effect quickly.
Our laboratories have identified several series of compounds that can increase EAAT2
expression through translational activation. Our current results indicate that these EAAT2
translational activators have significant protective effects in ALS and epilepsy animal
models, suggesting that this translational activation approach works well in mice and that
these drug-like compounds are worth further pursuit. In addition, a thorough understanding
of the mechanisms underlying translational regulation of EAAT2, such as identifying the
molecular targets of the compounds, signaling pathways involved in the regulation, and
translational activation processes, are very important for this novel drug-development effort.
Furthermore, a more detailed understanding of the therapeutic window for EAAT2
upregulation that is safe for humans is also needed.
We are still in the early stages of developing EAAT2 activator treatment as a therapeutic
strategy for preventing excitotoxicity. In our opinion, we expect that in the coming years,
more EAAT2 activators will be identified and evaluated in animal models of disease. The
already identified compounds, such as ceftriaxone and LDN-212320, will be further
developed to improve their pharmacological and bioactivity properties. The outcomes of
ceftriaxone trials in ALS patients will be revealed soon. The continuous development of
LDN-212320 may lead to a more potent and safe analog for human clinical trials. In
addition, we expect that LDN-212320 or its analog will be tested in more animal models of
disease, which will provide valuable information about the potential of these compounds for
multiple diseases. We also expect that the molecular mechanisms underlying LDN-212320-
activated EAAT2 translation will be uncovered in the coming years. Transition from
preclinical mouse studies to human clinical trials is difficult for most diseases; successful
trails in mice often fail in subsequent human trials. It is our great hope that the EAAT2
treatment strategy will be successful and greatly benefit patients suffering from
neurodegenerative diseases.
Acknowledgments
The authors are grateful to colleagues at Ohio State University and Brigham and Women’s Hospital who helped
advance the EAAT2 activator project.
Key Terms
Synaptic vesicle Stores neurotransmitters to be released at synapses
Synaptic cleft Very small gap between presynaptic and postsynaptic cells through
which neurotransmitters diffuse
Ionotropic
glutamate
receptors
Form an ion channel pore that allows the flow of K+, Na+ and in
some cases Ca2+ in response to glutamate binding
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Astrocytes Type of glial cell in the CNS that have multiple functions including
ionic concentration regulation in the intercellular space, uptake and/or
breakdown of neurotransmitters, and blood–brain barrier formation
Dementia Loss of brain function that impairs memory, thinking, language,
judgment, and behavior under certain diseases
Motor neurons Send impulses from the CNS to muscles, glands and other tissues
Substantia nigra Region of the brain structure located in the midbrain that is important
in reward, addiction and movement
Deep-brain
stimulation
Treatment that involves surgical implantation of a brain pacemaker,
capable of sending electrical impulses to specific parts of the brain
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Executive summary
Excitotoxicity: a common problem in neurodegenerative diseases
• Under disease conditions, elevated extracellular glutamate concentrations can
occur, which result in neuronal injury or death.
• The beneficial effects of currently available anti-excitotoxic drugs are very
limited. There is a need for better therapeutics.
EAAT2: a potential target for prevention of excitotoxicity
• Several lines of evidence indicate that upregulation of EAAT2 is a potential
therapeutic strategy for the prevention of excitotoxicity.
Searching for EAAT2 activators: a promising approach for the treatment of
neurodegenerative diseases
• Two approaches can be used to search for EAAT2 activators: transcriptional or
translational activation.
• β-lactam antibiotics, such as ceftriaxone, were identified as transcriptional
activators of EAAT2. It may be possible to develop new derivatives of
ceftriaxone with enhanced pharmacological and bioactivity properties.
• Several series of novel small molecules that can specifically increase EAAT2
protein expression through translational activation have recently been identified.
Further investigation into these small molecules is underway.
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Figure 1. Glutamatergic neurotransmission and excitotoxicity
(A) Under normal conditions, glutamate released from the presynaptic neuron activates
ionotropic glutamate receptors (NMDA and AMPA receptors) present on the postsynaptic
neuron. This results in the influx of Na+ and Ca2+ ions into the cell, leading to
depolarization and generation of an action potential. (B) Acute elevations of glutamate
(when the release of glutamate from presynaptic terminals and/or glial cells is increased) in
conditions such as stroke, neurotrauma and epilepsy cause severe neuronal injury or death.
(C) Chronic and mild elevations of glutamate (when the glutamate reuptake function is
impaired) such as Alzheimer’s disease, Parkinson’s disease and amylotrophic lateral
sclerosis cause neuronal damage. (D) Increased EAAT2 is a potential therapeutic strategy
for the prevention of excitotoxicity.
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AMPA: α-amino-3-hydroxy-5-methyl-4 isoxazolepropionate; NMDA: N-methyl-D-
aspartate.
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Figure 2.
Ceftriaxone and LDN-212320.
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